Divi’s Laboratories announced its financial results for the quarter ending September 30, 2024, showing impressive growth across key metrics. The pharmaceutical major reported a revenue from operations of ₹2,338 crore, marking a year-on-year (YoY) increase of 22.47% compared to ₹1,909 crore in the corresponding quarter last year. The revenue also saw a quarter-on-quarter (QoQ) rise of 10.39% from ₹2,118 crore in Q1 FY25.
The company’s net profit for Q2 FY25 came in at ₹510 crore, representing a significant 46.55% YoY growth compared to ₹348 crore in the same quarter of the previous year. This growth also reflects an 18.6% increase over the net profit of ₹430 crore reported in Q1 FY25.
For the half-year period ending September 30, 2024, Divi’s Laboratories achieved a consolidated total income of ₹4,640 crore, a 20.38% increase from ₹3,854 crore in the same period last year. The half-year PBT rose to ₹1,326 crore, compared to ₹961 crore in the previous year, while PAT reached ₹940 crore, up from ₹704 crore for the same period.
The robust growth in both revenue and profit for Divi’s Laboratories highlights strong performance in the company’s operations, reinforcing its position in the pharmaceutical sector. The company has attributed this growth to better operational efficiencies and improved market conditions.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
